Dermata Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Summary of Significant Accounting Policies (Tables)

Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2023

Summary of Significant Accounting Policies

Schedule of earnings per share, basic and diluted

		Three Months Ended June 30,								Six Months Ended June 30,
		2023				2022				2023				2022

Net loss		$	(1,701,364	)		$	(2,730,573	)		$	(3,941,506	)		$	(5,516,725	)

Weighted-average basic and diluted common shares			2,704,987				699,679				1,850,167				611,344

Basic and diluted net loss per common share		$	(0.63	)		$	(3.90	)		$	(2.13	)		$	(9.02	)

Schedule of potentially diluted basic earnings

		As of June 30,
		2023				2022
Common Stock options			102,074				62,582
Common Stock warrants			4,643,555				437,102
Total potentially dilutive securities			4,745,629				499,684